Dianthus Therapeutics (DNTH) director trades 7,750 shares under 10b5-1 plan
Rhea-AI Filing Summary
Dianthus Therapeutics, Inc. director Anne McGeorge reported option exercises and related sales of common stock. On August 10, 2026, she exercised options for 7,750 shares of common stock at exercise prices of $19.36 and $11.20 per share, then sold 7,750 shares in multiple transactions at weighted average prices between $106.79 and $111.63 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,750 shares ($748K approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
McGeorge Anne
Role
Director
Sold
7,750 shs ($845K)
Approx. gross sale proceeds
$845K
Approx. exercise cost
$97K
Approx. pre-tax spread
$748K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1 | 1,250 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1 | 6,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,250 | $19.36 | $24K |
| Exercise | Common Stock F1 | 6,500 | $11.20 | $73K |
| Sale | Common Stock F1, F2 | 1,450 | $107.58 | $156K |
| Sale | Common Stock F1, F3 | 2,800 | $108.38 | $303K |
| Sale | Common Stock F1, F4 | 1,800 | $109.30 | $197K |
| Sale | Common Stock F1, F5 | 1,000 | $110.64 | $111K |
| Sale | Common Stock F1, F6 | 700 | $111.41 | $78K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (6)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.79 to $107.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.84 to $108.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.89 to $109.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.05 to $111.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.15 to $111.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Key Figures
Options exercised: 7,750 shares
Exercise prices: $19.36 and $11.20 per share
Shares sold: 7,750 shares
+3 more
6 metrics
Options exercised
7,750 shares
Total shares underlying options exercised on August 10, 2026
Exercise prices
$19.36 and $11.20 per share
Stock option exercise prices for 1,250 and 6,500 shares, respectively
Shares sold
7,750 shares
Total common shares sold in multiple transactions on August 10, 2026
Weighted average sale prices
$107.58–$111.41 per share
Per reported sale rows; detailed ranges from $106.79 to $111.63
10b5-1 plan adoption date
May 11, 2026
Rule 10b5-1 trading plan governing the reported transactions
Option expiration dates
June 27, 2032 and September 10, 2033
Expiration of options originally exercisable in 2023 and 2024
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open market or private transaction financial
"transaction_code_description": "Sale in open market or private transaction""
FAQ
What did DNTH director Anne McGeorge report in this Form 4?
Anne McGeorge reported exercising stock options for 7,750 shares of Dianthus Therapeutics common stock and selling 7,750 shares in market transactions on August 10, 2026, under a pre-arranged Rule 10b5-1 trading plan.
How many Dianthus Therapeutics (DNTH) options did Anne McGeorge exercise?
She exercised options covering 7,750 shares of Dianthus Therapeutics common stock. The options had exercise prices of $19.36 and $11.20 per share, originally exercisable on June 28, 2023, and May 23, 2024, respectively.
Were Anne McGeorge’s DNTH trades under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on May 11, 2026, indicating the trades followed a pre-established schedule rather than discretionary timing.
What types of securities are involved in Anne McGeorge’s DNTH Form 4?
The filing reports transactions in stock options (right to buy) and common stock. Options were exercised to acquire 7,750 common shares, and the same number of common shares were then sold in market transactions on August 10, 2026.
Does the Form 4 show Anne McGeorge’s remaining DNTH holdings?
The structured data lists the reported transactions but does not provide a specific figure for shares owned after these trades. Only the exercised option amounts and the corresponding share sales on August 10, 2026 are detailed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
